Play Video

WELCOME TO THE NEW DR. GOODENOWE RESEARCH INSTITUTE

Play Video

Dr. Goodenowe’s expanded research facilities will enable him and his collaborators worldwide to understand disease in order to restore health, and develop meaningful solutions for achieving and maintaining vitality well past age 100.

Our new, 10,000+ square foot facility is being custom built by Dr. Goodenowe to house his advanced biochemistry technologies and supportive infrastructure.

Dr. Goodenowe’s laboratory is his playground. Here he dives into the complex biochemical systems of our lives and delivers real solutions for longevity.

The biochemistry technology is now installed (and more coming!).

Advanced MRI technology is in development.

On-site doctor training is ready soon.

And in-person services are almost complete.

Population Health

The real human population is messy. Population health is about designing and executing clinical trials for the real world and for real people living normal lives. Population health is about changing disease incidence rates and improving functions as we age.  

My research focuses on real world solutions for every person. “One size fits all” fits nobody.

Population Health

The real human population is messy. Population health is about designing and executing clinical trials for the real world and for real people living normal lives. Population health is about changing disease incidence rates and improving functions as we age.  

My research focuses on real world solutions for every person. “One size fits all” fits nobody.

I have had the good fortune of observing firsthand the significant, clinical benefits in my patients with neurodegenerative disorders for whom I’ve prescribed plasmalogen therapy."

Mitchel Fleisher M.D., D.Ht., D.A.B.F.M., Dc.A.B.C.T. | Medical Director, Center for Integrative & Regenerative Medicine

BREAKING ALZHEIMER’S


Dr. Goodenowe’s book Breaking Alzheimer’s: A 15 Year Crusade to Expose the Cause and Deliver the Cure launched in 2021, where he outlines the story of plasmalogens.

"A paradigm-altering view of Alzheimer’s."

Dale Bredesen, MD | Author of The New York Times Bestseller, The End of Alzheimer’s
Breaking Alzheimer's Book

BREAKING RCDP


RCDP is a rare childhood genetic disease. Affected children do not have plasmalogens. As part of Dr. Goodenowe’s Childhood Peroxisomal Disease Foundation, where he offers his biochemical research strategies free of charge to affected families, Dr. Goodenowe is specifically breaking down RCDP (a type of peroxisomal disease).

RESEARCH COLLABORATIONS

Bio Serve Logo
Precision Med Logo
Duke University Logo

PATENTS

Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof

Issued September 19, 2006 Canada 2298181
Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases
Issued September 19, 2006 Canada 2298181
Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging

Issued September 19, 2006 Canada 2298181
Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Methods for the Treatment of Elevated Cholesterol Levels (Method for Lowering Cholesterol)
Issued September 19, 2006 Canada 2298181
Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.
Methods for the Treatment of Senile Dementia of the Alzheimer’s Type
Issued September 19, 2006 Canada 2298181
Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.
Method and Apparatus for Fourier Transform Ion Cyclotron Resonance Mass Spectrometry
Issued September 19, 2006 Canada 2298181
Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.
Methods for the Diagnosis of Dementia and other Neurological Disorders
Issued September 19, 2006 Canada 2298181
Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers
Issued September 19, 2006 Canada 2298181
Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.
Method of Non-Targeted Complex Sample Analysis
Issued September 19, 2006 Canada 2298181
Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

articles